ROCHE HOLDING AG-BR (RHO.DE) Stock Price, Forecast & Analysis
Europe • Frankfurt Stock Exchange • FRA:RHO • CH0012032113
RHO.DE Key Statistics, Chart & Performance
The current stock price of RHO.DE is 398.6 EUR. In the past month the price increased by 7.32%.
RHO.DE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RHO.DE.
RHO.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to RHO.DE. While RHO.DE has a great profitability rating, there are some minor concerns on its financial health.
RHO.DE Financial Highlights
Over the last trailing twelve months RHO.DE reported a non-GAAP Earnings per Share(EPS) of 21.47. The EPS increased by 5.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.31% | ||
| ROA | 9.95% | ||
| ROE | 32.88% | ||
| Debt/Equity | 1.06 |
RHO.DE Forecast & Estimates
27 analysts have analysed RHO.DE and the average price target is 349.14 EUR. This implies a price decrease of -12.41% is expected in the next year compared to the current price of 398.6.
For the next year, analysts expect an EPS growth of 6.29% and a revenue growth 2.32% for RHO.DE
RHO.DE Ownership
RHO.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.69 | 197.812B | ||
| SAN | SANOFI | 9.51 | 195.855B | ||
| SNW | SANOFI | 9.5 | 195.638B | ||
| MRK | MERCK KGAA | 14.13 | 53.065B | ||
| UCB | UCB SA | 25.48 | 52.168B | ||
| UNC | UCB SA | 25.52 | 51.37B | ||
| BAYN | BAYER AG-REG | 9.37 | 44.027B | ||
| 1BAYN | BAYER AG-REG | 9.17 | 44.008B | ||
| IPN | IPSEN | 11.93 | 11.365B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 10.104B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About RHO.DE
Company Profile
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Company Info
ROCHE HOLDING AG-BR
Grenzacherstrasse 124
Basel BASEL-STADT CH
Employees: 103249
Phone: 41616881111
ROCHE HOLDING AG-BR / RHO.DE FAQ
Can you describe the business of ROCHE HOLDING AG-BR?
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
What is the stock price of ROCHE HOLDING AG-BR today?
The current stock price of RHO.DE is 398.6 EUR. The price decreased by -0.1% in the last trading session.
Does ROCHE HOLDING AG-BR pay dividends?
ROCHE HOLDING AG-BR (RHO.DE) has a dividend yield of 2.8%. The yearly dividend amount is currently 11.03.
What is the ChartMill rating of ROCHE HOLDING AG-BR stock?
RHO.DE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the GICS sector and industry of RHO stock?
ROCHE HOLDING AG-BR (RHO.DE) operates in the Health Care sector and the Pharmaceuticals industry.
How many employees does ROCHE HOLDING AG-BR have?
ROCHE HOLDING AG-BR (RHO.DE) currently has 103249 employees.
What is the next earnings date for RHO stock?
ROCHE HOLDING AG-BR (RHO.DE) will report earnings on 2026-04-23.